Rise in Prevalence of Infectious Diseases Expected to Drive Global Blood Screening Market: Ken Research REQUEST FOR SAMPLE REPORT Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Buy Now The blood screening is a medical process that is conducted to examine the blood over a specific condition and it further helps in monitoring disease with a variety of other conditions associated to infection or the disease. The blood screening technology is widely used over various fields of diagnostics of diseases such as HIV, Cancer, and infections. Additionally, blood screening also helps in the growth of prominent diseases incorporation of nucleic acid amplification test and the other advancements in blood screening tests. As a result, demand & adoption for blood screening would increase thereby, making its way for the growth of the market. According to study, “Global Blood Screening Market to reach USD 3.94 billion by 2026” the key companies operating in the global blood screening market is Grifols S.A, Abbott Laboratories, F. Hoffmann-La Rochen AG, Becton, Dickson and Company, Biomerieux, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics, Danaher Corporation, and Siemens Healthineers AG. Based on the product, the blood screening market is segmented as instruments, reagents & kits and software & services. The reagents & kits segment is further sub-segmented as ELISA kit, NAT kit, and others. NAT reagents include enzymes & polymerases, probes & primers, standards & controls, nucleotides & solutions, buffers, and labeling & detection reagents. Additionally, ELISA reagents & kits include immunosorbents, conjugates (an antigen or antibody-conjugated enzyme), controls, and others. Based on disease type, the market is segmented as respiratory diseases, cholesterol, HIV/aids, cold & flu, diabetes mellitus, oncology, infectious diseases, others. Based on technology, the market is segmented as ELISA technology, Nucleic Acid Testing (NAT) technology (Real-time PCR and Transcription Mediated Amplification (TMA)), platform (Fluorescence Immunoassays (FIA), Chemiluminescence Immunoassay (CLIA) and Colorimetric Immunoassay (CI)), Next Generation Sequencing (NGS), Western Blot Assays, rapid tests, and others. In addition, based on end-user, the market is segmented as hospitals, blood banks, and others. The blood screening market is driven by an increase in the prevalence of infectious diseases, followed by a rise in awareness about healthcare, growth in technological advancements in blood screening technologies, increase in number of blood donations, rise in healthcare initiatives by government, increase in healthcare expenditure, and a surge in adoption of nucleic acid amplification test (NAT). However, the dearth of skilled manpower, stringent regulatory approvals and high operating costs may impact the market. Moreover, introduction of pathogen reduction technology or microbiology screening & multiplexing are key opportunities for the market. Based on geography, the North-American region holds a major share in the global blood screening market owing to the rise in the prevalence of infectious diseases along with an increase in demand for donated blood in the region. Whereas, the Asian-Pacific and European regions are anticipated to witness higher growth rate due to rise in public-private the initiative aimed towards increasing advance research practices and growth in investment to promote blood screening research over the forecast period. In upcoming years, it is projected that the future of the global market will be bright as a result of the presence of the well-established infrastructure for hospitals & clinical laboratories coupled with the rise in prevalence of newer pathogens during the forecast period. The global blood screening market is valued approximately at the US $2.02 billion in 2018 and is expected to grow with a healthy growth rate of more than 8.70% over the forecast period 2019 to 2026. For More Information on the Research Report, refer to below links: – Global Blood Screening Market Growth Related Report: – Global Blood Screening Market _Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025 Contact Us: – Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249 Tags: Abbott Laboratories Blood Screening Market, Asia Pacific Blood Screening Market, Bio-Rad Blood Screening Market Revenue, Danaher Blood Screening Market Growth Rate, Europe Blood Screening Market Share, Global Blood Screening Industry Research Report, Global Blood Screening Market Analysis, Global Blood Screening Market Forecast, Global Blood Screening Market Future Outlook, Global Blood Screening Market Growth Rate, Global Blood Screening Market Major Players, Global Blood Screening Market Research Report, Global Blood Screening Market Revenue, Global Blood Screening Market Share, Global Blood Screening Market Size, Grifols S.A Blood Screening Market Share, North America Blood Screening Market, Russia Blood Screening Market Growth, Siemens Blood Screening Market Outlook, Thermo Fisher Blood Screening Market